Stockscreener 앱 받기
821.34
0.14%
-2.28
Lilly Eli Co 주식(LLY)의 최신 뉴스
3 No-Brainer Stocks to Buy in May - The Motley Fool
Eli Lilly’s Strategic Adjustments and Growth Prospects Reinforce Buy Rating Despite Setbacks - TipRanks
Eli Lilly First Quarter 2025 Earnings: EPS Misses Expectations - Yahoo
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash? - Yahoo Finance
This pill could forever change how people lose weight3 May 2025Time Magazine EuropeReadly | All magazines - Readly | All magazines - one magazine app subscription
Eli Lilly and Company (NYSE:LLY) Q1 2025 Earnings Call Transcript - Insider Monkey
Eli Lilly (LLY) Stock Rating Maintained by UBS Despite Price Tar - GuruFocus
Eli Lilly (NYSE:LLY) Announces Promising Trial Data And Updates 2025 Guidance - Yahoo Finance
UBS cuts Eli Lilly stock target to $1,050, maintains Buy rating - Investing.com UK
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday - AOL.com
Eli Lilly’s Stock Selloff Is Overdone, Analysts Say. Here’s Why. - MSN
Cantor Fitzgerald maintains $975 target on Eli Lilly stock By Investing.com - Investing.com India
Cantor Fitzgerald maintains $975 target on Eli Lilly stock - Investing.com
Eli Lilly Stays Strong Despite CVS Dropping Key Drug - Finimize
Leerink sees Eli Lilly stock dip as buying chance, keeps $944 target - Investing.com India
Lilly to participate in Bank of America Securities 2025 Healthcare Conference - Quantisnow
Eli Lilly CFO to Share Strategic Insights at Major Bank of America Healthcare Conference - Stock Titan
Positive Outlook for Eli Lilly & Co. Despite Competitive Challenges - TipRanks
Eli Lilly (LLY) Price Target Reduced by UBS Analyst Despite Stro - GuruFocus
Eli Lilly (LLY) sell-off 'overdone' on CVS move on WegovyLeerink - StreetInsider
Eli Lilly Tackles CVS Health's Cut In Zepbound Coverage - Finimize
Street View: Eli Lilly well positioned in weight-loss market despite CVS's decision - TradingView
Eli Lilly selloff on CVS Wegovy news overdone, says JPMorgan - TipRanks
Eli Lilly & Co: Strong Market Position and Growth Potential Amid Competitive Pressures - TipRanks
Decoding Eli Lilly and Co (LLY): A Strategic SWOT Insight - GuruFocus
Eli Lilly and Co (LLY) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Eli Lilly and Co (LLY) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Innovations - GuruFocus
Eli Lilly (LLY) Faces Market Cap Drop Amid Competitive Pressure - GuruFocus
Eli Lilly (LLY) Prepares for Potential Tariffs on Pharmaceuticals - GuruFocus
Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal - MSN
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge - Reuters
Friday Five – Pharma's tariff-proofing playbook, Novo slims Lilly's lead, vaccine policy shakeup…and more - FirstWord Pharma
Obesity Drug Price Wars Heating Up as CVS Picks Novo Over Lilly - Bloomberg.com
Lilly Cuts Earnings Guidance on Research Charges, Shares Fall - Bloomberg.com
Eli Lilly (LLY) Stock: Shares Tumble 10% Despite 45% Revenue Surge in Q1 2025 - CoinCentral
Eli Lilly and Company (LLY) Stock Price, News, Quote & History - Yahoo Finance
CVS Drops Lilly’s Zepbound from Preferred Coverage in Novo Win - Bloomberg.com
Eli Lilly Shares Tumble 10% After Q1 Earnings Miss Wall Street Estimates - Yahoo
Eli Lilly (LLY) Gains WHO Support for Obesity Drug Zepbound - GuruFocus
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge By Reuters - Investing.com
Is Eli Lilly and Company (LLY) the Best Growth Stock to Buy for the Next 3 Years? - Insider Monkey
Eli Lilly CEO waves off CVS-Novo Nordisk deal: 'It feels a little like last decade' - Yahoo Finance
Why Eli Lilly (LLY) Stock Is Nosediving - Yahoo Finance
Eli Lilly, Microsoft Lead Market Cap Stock Movers on Thursday By Investing.com - Investing.com Nigeria
Eli Lilly Earnings: Solid Performance Overshadowed by Novo’s Obesity Coverage Win - Morningstar
Eli Lilly (NYSE:LLY) Reports Strong Q1 Growth Despite Lowered 2025 EPS Guidance - Yahoo Finance
Eli Lilly, Microsoft Lead Market Cap Stock Movers on Thursday - Investing.com
CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone - Seeking Alpha
Lilly’s Q1 2025 revenue jumps 45%, but CVS shift boosts Novo’s Wegovy - Yahoo Finance
Eli Lilly's earnings beat is clouded by Novo news. What it means for investors - CNBC
Why Eli Lilly Stock Is Sinking Today - MSN
Lilly star weight-loss drug Zepbound faces coverage challenge from CVS Health - KRON4
Eli Lilly CEO says tariffs are not the answer, urges Trump to move fast on trade deals - IndyStar
Eli Lilly and Company (LLY) stock price, news, quote and history - Yahoo
Eli Lilly’s Stock Tumbles as Firm Cuts EPS Guidance Despite Strong Q1 - Tokenist
Eli Lilly slides, CVS earnings, Qualcomm's soft guidance - Yahoo Finance
'Declare victory and move on': Eli Lilly CEO on Trump tariff threat - Yahoo Finance
0.77%
자본화:
|
볼륨(24시간):